Search
Vapitadine
go.drugbank.com/drugs/DB05738ExperimentalAn advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis
Eprinomectin
go.drugbank.com/drugs/DB11405ExperimentalVet approvedCategories: Compounds used in a research, industrial, or household settingXR5944
go.drugbank.com/drugs/DB06364ExperimentalXR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Seltorexant
go.drugbank.com/drugs/DB14961InvestigationalSeltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
LY-2624803
go.drugbank.com/drugs/DB15092InvestigationalLY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).
Dimethandrolone Undecanoate
go.drugbank.com/drugs/DB16141InvestigationalDimethandrolone Undecanoate is under investigation in clinical trial NCT03455075 (Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men).
Avizakimab
go.drugbank.com/drugs/DB18842InvestigationalAvizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).
NCX 950
go.drugbank.com/drugs/DB05849ExperimentalNCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
Levilimab
go.drugbank.com/drugs/DB16387InvestigationalLevilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
MLN2704
go.drugbank.com/drugs/DB06513InvestigationalA Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.